ID
14629
Description
Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00072631
Link
https://clinicaltrials.gov/show/NCT00072631
Keywords
Versions (1)
- 4/24/16 4/24/16 -
Uploaded on
April 24, 2016
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Advanced Non Small Cell Lung Cancer NCT00072631
Eligibility Advanced Non Small Cell Lung Cancer NCT00072631
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Description
breast cancer or skin cancer
Data type
boolean
Alias
- UMLS CUI [1]
- C0678222
- UMLS CUI [2]
- C0007114
Description
brain metastases
Data type
boolean
Alias
- UMLS CUI [1]
- C0220650
Description
hypersensitivity to minocycline
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0020517
- UMLS CUI [1,2]
- C0026187
Description
serious cardiac disease
Data type
boolean
Alias
- UMLS CUI [1]
- C0018799
Description
serious eye conditions
Data type
boolean
Alias
- UMLS CUI [1]
- C0015397
Description
nhibitors of egfr
Data type
boolean
Alias
- UMLS CUI [1]
- C1443775
Similar models
Eligibility Advanced Non Small Cell Lung Cancer NCT00072631
- StudyEvent: Eligibility
C0232804 (UMLS CUI [2])
C0005953 (UMLS CUI [3])
C0007114 (UMLS CUI [2])
C0026187 (UMLS CUI [1,2])